scholarly journals Profiling Serum Antibodies with a Pan Allergen Phage Library Identifies Key Wheat Allergy Epitopes

2021 ◽  
Author(s):  
Daniel R. Monaco ◽  
Brandon M. Sie ◽  
Thomas R. Nirschl ◽  
Audrey C. Knight ◽  
Hugh A. Sampson ◽  
...  

Abstract Allergic reactions occur when IgE molecules become crosslinked by antigens such food proteins. The physiologic consequences range from mild to life-threatening. Here we create the ‘AllerScan’ bacteriophage display library for efficiently profiling allergic antibodies to characterize binding specificities associated with known allergens. AllerScan enables sensitive and unbiased characterization of circulating IgE and IgG antibody reactivities against thousands of allergenic proteins from hundreds of organisms at peptide resolution. Using AllerScan to analyze food allergy reactivities, we identify robust anti-wheat IgE reactivities in wheat allergic patients but not in wheat-sensitized individuals. Meanwhile, a wheat allergen epitope, alpha purothionin, elicits dominant IgE responses among allergic patients but frequent IgG responses among sensitized and non-allergic patients; a double-blind placebo-controlled trial shows that alpha purothionin reactivity, among others, is strongly modulated by oral immunotherapy. Our proof-of-principle results thus suggest that AllerScan to be a high-throughput platform for unbiased analysis of allergic antibody fine specificities.

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Daniel R. Monaco ◽  
Brandon M. Sie ◽  
Thomas R. Nirschl ◽  
Audrey C. Knight ◽  
Hugh A. Sampson ◽  
...  

AbstractAllergic reactions occur when IgE molecules become crosslinked by antigens such as food proteins. Here we create the ‘AllerScan’ programmable phage display system to characterize the binding specificities of anti-allergen IgG and IgE antibodies in serum against thousands of allergenic proteins from hundreds of organisms at peptide resolution. Using AllerScan, we identify robust anti-wheat IgE reactivities in wheat allergic individuals but not in wheat-sensitized individuals. Meanwhile, a key wheat epitope in alpha purothionin elicits dominant IgE responses among allergic patients, and frequent IgG responses among sensitized and non-allergic patients. A double-blind, placebo-controlled trial shows that alpha purothionin reactivity, among others, is strongly modulated by oral immunotherapy in tolerized individuals. AllerScan may thus serve as a high-throughput platform for unbiased analysis of anti-allergen antibody specificities.


2010 ◽  
Vol 125 (2) ◽  
pp. AB58 ◽  
Author(s):  
S.M. Jones ◽  
A.M. Scurlock ◽  
L. Pons ◽  
T.T. Perry ◽  
A.R. Morgan ◽  
...  

2018 ◽  
Vol 3 (2) ◽  
pp. 85-94 ◽  
Author(s):  
Sandra Andorf ◽  
Natasha Purington ◽  
Whitney M Block ◽  
Andrew J Long ◽  
Dana Tupa ◽  
...  

2019 ◽  
Vol 143 (2) ◽  
pp. AB155
Author(s):  
Julie Wang ◽  
Douglas T. Johnston ◽  
Jay A. Lieberman ◽  
Christine Birchwood ◽  
Sarah Acaster ◽  
...  

Author(s):  
Jiankai Liu ◽  
Baoying Huang ◽  
Guifan Li ◽  
Xianyun Chang ◽  
Yafei Liu ◽  
...  

Abstract Background Control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic needs effective vaccines. Methods In a phase 2 randomized, double-blind, placebo-controlled trial, 500 adults aged 18-59 years or ≥60 years were randomized in 2:2:1 ratio to receive 3 doses of 5-μg or 10-μg of a SARS-CoV-2 inactivated vaccine, or placebo separated by 28 days. Adverse events (AEs) were recorded through Day 28 after each dosing. Live virus or pseudovirus neutralizing antibodies, and receptor binding domain (RBD-IgG) antibody were tested after the second and third doses. Results Two doses of the vaccine elicited geometric mean titers (GMTs) of 102-119, 170-176, and 1449-1617 for the three antibodies in younger adults. Pseudovirus neutralizing and RBD-IgG GMTs were similar between older and younger adults. The third dose slightly (<1.5 folds) increased GMTs. Seroconversion percentages were 94% or more after two doses, which were generally similar after three doses. The predominant AEs were injection-site pain. All the AEs were grade 1 or 2 in intensity. No serious AE was deemed related to study vaccination. Conclusions Two doses of this vaccine induced robust immune response and had good safety profile. A third dose given 28 days after the second dose elicited limited boosting antibody response.


Sign in / Sign up

Export Citation Format

Share Document